Jazz Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. 

CEO
Renée D. Galá
CEORenée D. Galá
Employees
2,800
Employees2,800
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2005
Founded2005
Employees
2,800
Employees2,800

JAZZ Key Statistics

Market cap
8.32B
Market cap8.32B
Price-Earnings ratio
-20.29
Price-Earnings ratio-20.29
Dividend yield
Dividend yield
Average volume
753.52K
Average volume753.52K
High today
$138.13
High today$138.13
Low today
$135.02
Low today$135.02
Open price
$136.02
Open price$136.02
Volume
1.09M
Volume1.09M
52 Week high
$148.06
52 Week high$148.06
52 Week low
$95.49
52 Week low$95.49

JAZZ News

Simply Wall St 5d
Are Jazz Pharmaceuticals Shares Set for a Rebound After Recent Drug Approval in 2025?

If you are weighing your next move with Jazz Pharmaceuticals, you are not alone. Whether you are cautiously optimistic after the recent volatility in the biotec...

Are Jazz Pharmaceuticals Shares Set for a Rebound After Recent Drug Approval in 2025?

Analyst ratings

95%

of 20 ratings
Buy
95%
Hold
5%
Sell
0%

People also own

Based on the portfolios of people who own JAZZ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.